The invention relates to a cocktail against Aids, consisting of a commercially available anti-tumoral drug (1), such as doxorubicin, idarubicin, etoposide, chlorambucil, cisplatin, melphalan or bortezomib, a P-glycoprotein inhibitor (2), such as tariquidar, cetoconazol, verapamil, amiodarone or quinidine, and a commercially available antiviral agent of the viricidal type (3) which acts directly on the virus, such as N,N-dichloro-2,2-dimethyltaurine (NVC-422) or the HIVcide nanoviricide, and designed to combat and completely eliminate the Aids virus from the organism.

The invention relates generally to a silvestrol molecule activated with a leaving group. The invention further relates generally to an antibody-drug conjugate comprising an antibody conjugated by a linker to one or more silvestrol drug moieties and methods of treatment.

The invention relates generally to a silvestrol molecule activated with a leaving group. The invention further relates generally to an antibody-drug conjugate comprising an antibody conjugated by a linker to one or more silvestrol drug moieties and methods of treatment.

Disclosed is a method of detecting a concentration of a biomarker in a human subject having or being at risk of developing Alzheimer's disease or Mild Cognitive Impairment (MCI). Also disclosed is a process for detecting a concentration of a biomarker in a human subject having or being at risk of developing Alzheimer's disease or Mild Cognitive Impairment (MCI) comprising (a) detecting a first concentration of lipocalin-PDS/TTR complex in a blood sample or urine sample from the subject, (b) determining a second concentration of PDS/TTR complex in a blood sample or urine sample from an unaffected individual, and (c) comparing the first and second concentrations, wherein a lower first concentration as compared to the second concentration is indicative of the subject having or being at risk of developing Alzheimer's disease.

To provide a superior anti-human NGF antibody Fab fragment that maintains a high neutralizing activity, and that reduces systemic side-effects arising from systemic exposure while expressing a local drug effect, and means for treating postoperative pain by using such antibody fragment. An anti-human NGF antibody Fab fragment comprising a heavy-chain fragment consisting of the amino acid sequence shown by SEQ ID NO:5 and a light-chain consisting of the amino acid sequence shown by SEQ ID NO: 8.

This invention relates to assays which screen for compounds that modulate taste elicited by the T1R2/T1R3 sweet taste receptor which include a novel counter screen to eliminate false positives. In addition, the invention contemplates assays which screen for compounds that modulate taste elicited by the T1R1/T1R3 umami taste receptor which include a novel counter screen to eliminate false positives. Preferably the assays are conducted in high throughput format thereby enabling the screening of many hundreds of different compounds whereby the counter screen significantly improves assay efficiency. Further, the invention relates to the use of the compounds identified in the subject screening assays to modulate T1R associated taste perception.

Disclosed herein are methods for reducing or arresting an increase in a Neuropathy Impairment Score (NIS) or a modified NIS (mNIS+7) in a human subject by administering an effective amount of a transthyretin (TTR)-inhibiting composition.

Disclosed herein are methods for reducing or arresting an increase in a Neuropathy Impairment Score (NIS) or a modified NIS (mNIS+7) in a human subject by administering an effective amount of a transthyretin (TTR)-inhibiting composition.

According to the invention there is provided a compound of Formula (I) in which: A is a C.sub.2-8 alkylene group; R.sup.1, R.sup.2, R.sup.3, and R.sup.4 are independently selected from hydrogen, C.sub.1-4 alkyl, C.sub.2-4 dihydroxyalkyl in which the carbon atom attached to the nitrogen atom does not carry a hydroxyl group and no carbon atom is substituted by two hydroxyl groups, or R.sup.2 and R.sup.3 together form a C.sub.2-6 alkylene group which with the nitrogen atom to which R.sup.2 and R.sup.3 are attached forms a heterocyclic ring; X.sub.1, X.sub.2 and X.sub.3 are independently selected from hydrogen, hydroxyl, NR.sup.1-A-NR.sup.2R.sup.3R.sup.4+(Z.sup.m−).sub.1/m, for halogeno amino, C.sub.1-4 alkoxy or C.sub.2-8 alkanoyloxy; and (Z.sup.m−).sub.1/m is an anion of charge m; or a derivative in which the group NR.sup.1 is quaternarized.

Embodiments are directed to methods of examining preimplantation factor (PIF) binding to a subject's circulating immune cells as a marker for immune dysregulation. Some embodiments are directed to methods of detecting a level of immune dysregulation sufficient to cause recurrent pregnancy loss (RPL), methods of detecting a level of immune dysfunction sufficient to cause endometriosis, and methods of detecting a level of immune dysfunction comprising administering an effective amount of PIF or an analog thereof, and examining its binding to circulating immune cells. Within those methods, an about twenty percent change in PIF binding to a subject's circulating immune cells indicates a level of immune dysfunction.